FDA Asks Attention-Deficit Hyperactivity Disorder (ADHD) Drug Manufacturers to Develop Patient Medication Guides

FDA has directed the manufacturers of all drug products approved for the treatment of Attention-Deficit Hyperactivity Disorder (ADHD) to develop patient Medication Guides to alert patients to possible cardiovascular risks and risks of adverse psychiatric symptoms associated with the medicines, and to advise them of precautions that can be taken.

CLICK MEDICATION GUIDE OR LABEL FOR INFORMATION BELOW:

Drugs

Note: This page links to PDF files which require the free Adobe Acrobat Reader.

Adderall (mixed salts of a single entity amphetamine product) Tablets	Medication Guide	Label
Adderall XR (mixed salts of a single entity amphetamine product) Extended-Release Capsules	Medication Guide	Label
Concerta (methylphenidate hydrochloride) Extended-Release Tablets	Medication Guide	Label
Daytrana (methylphenidate) Transdermal System	Medication Guide	Label
Desoxyn (methamphetamine hydrochloride) Tablets	Medication Guide	Label
Dexedrine (dextroamphetamine sulfate) Spansule Capsules and Tablets	Medication Guide	Label
Focalin (dexmethylphenidate hydrochloride) Tablets	Medication Guide	Label
Focalin XR (dexmethylphenidate hydrochloride) Extended-Release Capsules	Medication Guide	Label
Metadate CD (methylphenidate hydrochloride) Extended-Release Capsules	Medication Guide	Label
Methylin (methylphenidate hydrochloride) Oral Solution	Medication Guide	Label
Methylin (methylphenidate hydrochloride) Chewable Tablets	Medication Guide	Label
Ritalin (methylphenidate hydrochloride) Tablets	Medication Guide	Label
Ritalin SR (methylphenidate hydrochloride) Sustained-Release Tablets	Medication Guide	Label
Ritalin LA (methylphenidate hydrochloride) Extended-Release Capsules	Medication Guide	Label
Strattera (atomoxetine hydrochloride) Capsules	Medication Guide	Label